Mitologics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Mitologics is a specialized, Paris-based CRO offering mitochondrial-focused assay services for toxicity and efficacy testing. Leveraging its proprietary MiToxView platform, the company serves a diverse global clientele across pharma, biotech, cosmetics, and agrochemistry, helping them de-risk development by identifying mitochondrial liabilities. As a privately held, revenue-generating service provider with CIR accreditation, Mitologics has established a strong reputation for scientific rigor and strategic project support in the niche but critical field of mitochondrial biology.

MetabolicRare Disease

Technology Platform

Proprietary suite of in vitro mitochondrial integrity and functionality assays, including the MiToxView platform, to measure parameters like oxidative phosphorylation, membrane potential, ROS, and ATP in healthy and pathological cell models.

Opportunities

Growing regulatory emphasis on mitochondrial safety in drug development creates sustained demand.

Expansion into claims substantiation for the cosmetic and nutraceutical industries offers a high-growth adjacent market.

The rise of mitochondrial-targeting therapies for metabolic, neurodegenerative, and rare diseases increases need for specialized efficacy testing services.

Risk Factors

Business is concentrated on a single scientific niche (mitochondrial biology), creating dependency on its continued relevance.

Faces potential competition from larger CROs developing internal capabilities or lower-cost academic cores.

Revenue is tied to client R&D budgets, which are cyclical and sensitive to economic downturns.

Competitive Landscape

Mitologics competes in a specialized segment of the preclinical CRO market. Direct competitors may include other boutique CROs focusing on organelle-specific toxicology (e.g., hepatotoxicity CROs) and the internal discovery biology/toxicology teams of large pharma. Its key competitive advantages are deep expertise, a proven track record with top-tier clients, and a service model that provides strategic interpretation beyond data delivery.

More companies in Diagnostics & Precision Medicine →More companies in France →